Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Semeia

Explore full profile

AI-powered remote monitoring for chronic disease patients

Paris, FranceFounded 2017Health Tech & Medtech
Valuation $0–100M Latest valuation · 2026
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Semeia and the history behind them.

About Semeia

Sêmeia is a French health-tech company founded in 2017 by Daniel Szeftel, Pierre Hornus (CEO), and Mathieu Godart (CTO). The company is headquartered in Paris, with its research and development team located in Toulouse, a move influenced by the region's strong healthcare and AI ecosystem. Sêmeia specializes in developing remote medical monitoring solutions for patients with serious or chronic illnesses. The company's core offering is MedicWise, a digital medical device platform that uses artificial intelligence to collect and analyze patient data in real-time. This allows healthcare professionals to monitor patients remotely, identify those at highest risk of complications, treatment cessation, or re-hospitalization, and intervene at the most critical moments. The system automates the collection of health data, including biological analysis, from various sources like connected devices and health insurance reimbursement data, presenting it on a dashboard for care teams. This process helps to save medical teams valuable time by reducing unnecessary hospital visits. Sêmeia's solutions are applied across several therapeutic areas, with a leading presence in nephrology through its NephroWise product. Other specialized applications include MentalWise (mental health), OncoWise (oncology), and ImmunoWise (autoimmune diseases), with plans to expand into stroke and diabetes care. The company serves clients such as industrial players in the health sector, scientific societies, and the French National Health Insurance (Assurance Maladie). The company has secured significant funding to support its growth. After an initial funding round in 2020, Sêmeia raised approximately €8 million ($8.28M) in a Series B round in December 2022. Key investors include Orange Ventures, Malakoff Humanis, and Banque des Territoires. In a strategic move to consolidate its market position, Sêmeia also acquired competitor Optim'Care in December 2022. Keywords: remote patient monitoring, artificial intelligence, health-tech, chronic disease management, predictive analytics, medical software, digital health, telehealth, data analytics, decision support, nephrology, oncology, mental health, MedicWise, risk prediction, healthcare data, patient follow-up, medical alerts, connected devices, clinical decision support

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
Paris, France
Employees
63
Open positions
2
Dealroom signal
83.7/100
Industry
Health
Sub-industry
Health Platform
Sector
Health Tech & Medtech, Remote Monitoring, Tech for Patients, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, Digital Care, remote health monitoring, DT and LS, observatoire healthtech
Technology
Deep Tech
Business model
SaaS
Client focus
b2b
Investment activity
1 company, latest Dec 2022
Capital deployed
Preferred round
ACQUISITION

Latest news

Press, funding announcements and product moves mentioning Semeia.

See all news

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCEquity / VC May 2026 $23M $92M Orange Ventures · XAnge · Acton Capital · Mutuelles Impact
EARLY VCEquity / VC Dec 2022 $8.8M $35M Undisclosed
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021
2020
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Semeia website traffic

Latest recorded traffic for Semeia is 24K monthly website visits, up 196.3% over the last three months. Semeia's team grew 6.8% over the past year.

Latest monthly visits24K 3-month web change+196.3% 1-year team growth+6.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇫🇷 France100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Semeia on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Semeia’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.